A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. [electronic resource]
Producer: 20200427ISSN:- 1946-6242
- Animals
- Brain -- drug effects
- Disease Models, Animal
- Enzyme Inhibitors -- pharmacology
- Farnesyltranstransferase -- antagonists & inhibitors
- Female
- GTP-Binding Proteins -- antagonists & inhibitors
- Humans
- Induced Pluripotent Stem Cells -- drug effects
- Lysosomes -- drug effects
- Male
- Mice
- Mice, Transgenic
- Mutation
- Neurons -- drug effects
- Piperidines -- pharmacology
- Proteolysis -- drug effects
- Pyridines -- pharmacology
- RNA, Small Interfering -- genetics
- Tauopathies -- drug therapy
- Translational Research, Biomedical
- tau Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.